Corxel Pharmaceuticals Limited

About Corxel Pharmaceuticals Limited

CORXEL is a global biotech company dedicated to developing innovative cardiometabolic therapies. Their mission is to address urgent unmet needs in the prevention and treatment of cardiovascular and metabolic diseases, aiming to provide life-changing and potentially life-saving treatments to patients worldwide.

Products & Services

JX09:An investigational new drug with global breakthrough potential for the treatment of hypertension.

CX11:A drug in Phase 2 trials for the treatment of Type 2 Diabetes Mellitus.

Oral Small Molecule GLP-1 Receptor Agonist:A part of CORXEL's cardiometabolic pipeline, under development.

CARDAMYST™ (etripamil):A self-administered nasal spray for adults with Paroxysmal Supraventricular Tachycardia (PSVT), recently FDA-approved under Milestone.

Specialties

Cardiometabolic disease therapies Hypertension treatment Acute ischemic stroke treatment Type 2 Diabetes Mellitus treatment Obesity treatment Global clinical studies

Funding History

Debug: View Raw Funding Data

#	Type	Amount Fields	Date Fields	Investors
1	RT: Series D1 T: - FT: Series D1	A: 287000000 MR: - FA: $287 million FAN: 287000000	D: 2026-01-22 FD: 2026-01-22	10 investors

Series D1 Latest

2026-01-22

$287.0M

10 investors (Pro only)

Growth Metrics

+45%

Employee Growth

YoY

3.2x

Funding Growth

Last Round

12

Markets

Operating

10K+

Customers

Active

View 3 more growth metrics with Pro

Unlock All Metrics

Mock Up

Team & Leadership

S

Sandy Mou

Board Executive Director and Chief Executive Officer

K

Kevin Xie

Chief Financial Officer

B

Bo Liang

Senior Vice President, Head of Clinical Development - Metabolic

R

Rainy Zhou

Senior Vice President, Regulatory Affairs

C

Christine Dai

Chief Human Resources Officer

J

John Li

General Counsel & Chief Compliance Officer

View 3 more team members with Pro

Unlock Full Team Directory

Recent News